CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 75 of 113 entries

View as:

Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Phase: N/A Priority: Normal

NCT ID: NCT03143712 Org: User:

Start: 04/18/17 End: 06/14/17 Due: 06/14/18

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)

Phase: N/A Priority: Normal

NCT ID: NCT02707562 Org: User:

Start: 02/29/16 End: 11/30/16 Due: 11/30/17

GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT00989703 Org: User:

Start: 09/30/09 End: 01/31/10 Due: 01/31/11

A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis

Phase: N/A Priority: Normal

NCT ID: NCT03595618 Org: User:

Start: 08/14/18 End: 07/14/20 Due: 07/14/21

Bioavailability Study With GLPG1972

Phase: N/A Priority: Normal

NCT ID: NCT02851485 Org: User:

Start: 07/31/16 End: 08/31/16 Due: 08/31/17

Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01208753 Org: User:

Start: 09/30/10 End: 02/28/11 Due: 02/28/12

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04653467 Org: User:

Start: 11/06/20 End: 01/10/22 Due: 01/10/23

First-in-Human Single Ascending and Multiple Dose of GLPG0778

Phase: N/A Priority: Normal

NCT ID: NCT01278108 Org: User:

Start: 12/31/10 End: 05/31/11 Due: 05/31/12

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

Phase: N/A Priority: Normal

NCT ID: NCT01829321 Org: User:

Start: 04/30/13 End: 04/30/14 Due: 04/30/15

A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines

Phase: N/A Priority: Normal

NCT ID: NCT04137341 Org: User:

Start: 10/09/19 End: 12/13/19 Due: 12/13/20

Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal

NCT ID: NCT02738801 Org: User:

Start: 03/31/16 End: 05/02/17 Due: 05/02/18

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667

Phase: N/A Priority: Normal

NCT ID: NCT04097938 Org: User:

Start: 09/18/19 End: 07/06/20 Due: 07/06/21

Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04971746 Org: User:

Start: 07/19/21 End: 05/09/22 Due: 05/09/23

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04720183 Org: User:

Start: 01/11/21 End: 04/23/21 Due: 04/23/22

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04856358 Org: User:

Start: 04/27/21 End: 11/08/21 Due: 11/08/22

A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970

Phase: N/A Priority: Normal

NCT ID: NCT04708184 Org: User:

Start: 01/11/21 End: 02/25/21 Due: 02/25/22

GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01313598 Org: User:

Start: 03/31/11 End: 06/30/13 Due: 06/30/14

First-in-Human Single and Multiple Dose of GLPG2222

Phase: N/A Priority: Normal

NCT ID: NCT02662452 Org: User:

Start: 01/31/16 End: 05/31/16 Due: 05/31/17

First-in-Human Single Ascending Dose of GLPG0492

Phase: N/A Priority: Normal

NCT ID: NCT01130818 Org: User:

Start: 05/31/10 End: 09/30/10 Due: 09/30/11

Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205

Phase: N/A Priority: Normal

NCT ID: NCT04704739 Org: User:

Start: 01/13/21 End: 03/10/21 Due: 03/10/22

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Phase: N/A Priority: Normal

NCT ID: NCT02914600 Org: User:

Start: 03/17/17 End: 08/01/23 Due: 08/01/24

Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT01580644 Org: User:

Start: 01/31/12 End: 03/31/12 Due: 03/31/13

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Phase: N/A Priority: Normal

NCT ID: NCT01039103 Org: User:

Start: 12/31/09 End: 11/30/11 Due: 11/30/12

A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

Phase: N/A Priority: Normal

NCT ID: NCT03976648 Org: User:

Start: 07/18/19 End: 04/13/21 Due: 04/13/22

First-in-Human Exploratory Single Ascending Dose of GLPG0974

Phase: N/A Priority: Normal

NCT ID: NCT01496937 Org: User:

Start: 12/31/11 End: 02/29/12 Due: 02/28/13

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet	NCT03143712	Galapagos NV	user2@example.com	None	2017-04-18	2017-06-14	2018-06-14	-	-	2025-07-14
Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)	NCT02707562	Galapagos NV	user2@example.com	None	2016-02-29	2016-11-30	2017-11-30	-	-	2025-07-14
GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects	NCT00989703	Galapagos NV	user2@example.com	None	2009-09-30	2010-01-31	2011-01-31	-	-	2025-07-14
A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis	NCT03595618	Galapagos NV	user2@example.com	None	2018-08-14	2020-07-14	2021-07-14	-	-	2025-07-14
Bioavailability Study With GLPG1972	NCT02851485	Galapagos NV	user2@example.com	None	2016-07-31	2016-08-31	2017-08-31	-	-	2025-07-14
Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of GLPG0555 in Healthy Subjects	NCT01208753	Galapagos NV	user2@example.com	None	2010-09-30	2011-02-28	2012-02-28	-	-	2025-07-14
A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects	NCT04653467	Galapagos NV	user2@example.com	None	2020-11-06	2022-01-10	2023-01-10	-	-	2025-07-14
First-in-Human Single Ascending and Multiple Dose of GLPG0778	NCT01278108	Galapagos NV	user2@example.com	None	2010-12-31	2011-05-31	2012-05-31	-	-	2025-07-14
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis	NCT01829321	Galapagos NV	user2@example.com	None	2013-04-30	2014-04-30	2015-04-30	-	-	2025-07-14
A Study in Healthy Volunteers to Compare Different Tablet Formulations of the Test Medicine, GLPG1972, Against the Current Tablet Formulation, and to Assess the Effect Food Has on One of the Test Medicines	NCT04137341	Galapagos NV	user2@example.com	None	2019-10-09	2019-12-13	2020-12-13	-	-	2025-07-14
Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)	NCT02738801	Galapagos NV	user2@example.com	None	2016-03-31	2017-05-02	2018-05-02	-	-	2025-07-14
A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667	NCT04097938	Galapagos NV	user2@example.com	None	2019-09-18	2020-07-06	2021-07-06	-	-	2025-07-14
Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects	NCT04971746	Galapagos NV	user2@example.com	None	2021-07-19	2022-05-09	2023-05-09	-	-	2025-07-14
Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects	NCT04720183	Galapagos NV	user2@example.com	None	2021-01-11	2021-04-23	2022-04-23	-	-	2025-07-14
A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects	NCT04856358	Galapagos NV	user2@example.com	None	2021-04-27	2021-11-08	2022-11-08	-	-	2025-07-14
A Study to Assess Relative Bioavailability of and Effect of Food on a New Oral Tablet Formulation of GLPG3970	NCT04708184	Galapagos NV	user2@example.com	None	2021-01-11	2021-02-25	2022-02-25	-	-	2025-07-14
GLPG0187: Safety, Tolerability and Pharmacokinetics in Patients With Solid Tumors	NCT01313598	Galapagos NV	user2@example.com	None	2011-03-31	2013-06-30	2014-06-30	-	-	2025-07-14
First-in-Human Single and Multiple Dose of GLPG2222	NCT02662452	Galapagos NV	user2@example.com	None	2016-01-31	2016-05-31	2017-05-31	-	-	2025-07-14
First-in-Human Single Ascending Dose of GLPG0492	NCT01130818	Galapagos NV	user2@example.com	None	2010-05-31	2010-09-30	2011-09-30	-	-	2025-07-14
Evaluation of Mass Balance and Absolute Bioavailability of GLPG1205	NCT04704739	Galapagos NV	user2@example.com	None	2021-01-13	2021-03-10	2022-03-10	-	-	2025-07-14
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease	NCT02914600	Galapagos NV	user2@example.com	None	2017-03-17	2023-08-01	2024-08-01	-	-	2025-07-14
Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers	NCT01580644	Galapagos NV	user2@example.com	None	2012-01-31	2012-03-31	2013-03-31	-	-	2025-07-14
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)	NCT01039103	Galapagos NV	user2@example.com	None	2009-12-31	2011-11-30	2012-11-30	-	-	2025-07-14
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis	NCT03976648	Galapagos NV	user2@example.com	None	2019-07-18	2021-04-13	2022-04-13	-	-	2025-07-14
First-in-Human Exploratory Single Ascending Dose of GLPG0974	NCT01496937	Galapagos NV	user2@example.com	None	2011-12-31	2012-02-29	2013-02-28	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance